March 13-14, 2017
Washington, DC
Transporters play key roles in human physiology and pathophysiology, contributing to the absorption, distribution, metabolism and excretion of structurally- and pharmacologically-diverse drugs. Research on membrane transporters has exploded, with approximately half of all scientific research articles on transporters published within the last 10 years. Increasingly, drug developers and regulatory scientists are interested in transporters as mediators of clinically important drug-drug interactions, and as pharmacologically relevant targets. The International Transporter Consortium (ITC) has played a key role in informing regulatory policy through careful and critical evaluation of published research. The ITC continues to be a leader in this area in sponsoring and organizing the ‘Third Workshop on Membrane Transporters in Drug Development’. In this two-day workshop, participants will hear lectures from world-class transporter biologists from universities, regulatory agencies and pharmaceutical companies. These lectures cover a range of topics in transporter biology, including the endogenous function of transporters, emerging transporters of importance in drug development, computational modeling, genomics and biomarker probes of transporters. The workshop concludes with a session focusing on regulatory issues in transporter-mediated drug-drug interactions, with case studies representing perspectives of regulatory agencies (e.g., FDA and EMA) as well as a panel discussion involving experts in the field to address questions from the attendees.
Speaker Presentations
Speaker |
Presentation Title |
Jonathan Himmelfarb, University of Washington |
Renal transporters, kidney disease and toxicity |
Ronald Oude Elferink, Academic Medical Center Amsterdam |
Hepatic phospholipid and bile acid transport deficiencies: Therapeutic/clinical implications |
Jeffrey Miner, Ardea Biosciences |
Gout and uric acid; from disease to transporters to therapy |
Ken Korzekwa, Temple University |
Modeling intracellular concentrations with in vitro imaging and liver perfusion studies |
Kim Brouwer, University of North Carolina, Chapel Hill |
Imaging Studies with the Transporter Probe 99mTc-Mebrofenin Reveal Altered Hepatic Exposure in Patients with Non-Alcoholic Steatohepatitis (NASH) |
Yuichi Sugiyama, RIKEN |
Is prediction of tissue exposure from in vitro data using PBPK modeling possible? Confirmation by PET imaging to study the clinical disposition of membrane transporter substrates |
Adrian Ray, Gilead Sciences |
New developments in renal drug transport |
Jashvant Unadkat, University of Washington |
OATP2B1: in vitro, proteomic, and clinical PK relevance in GI and liver |
Yan Zhang, Incyte |
Emerging importance of nutrient transporter-mediated DDIs |
Avner Schlessinger, Mount Sinai School of Medicine |
Inhibitor Discovery for the Human GLUT1 from Homology Modelling and Virtual Screening |
Par Matsson, Uppsala University |
Computational modelling to predict the functions and impact of drug transporters |
Aleksandra Galetin, University of Manchester |
PBPK modelling of renal impairment – what is missing? |
Mikko Niemi, University of Helsinki |
Massively parallel sequencing of drug transporters - SLCO1B1 and beyond |
Kathy Giacomini, University of California San Francisco |
Genomewide Studies Reveal Transporters as Determinants of Drug Response |
Ana Pajor, University of California San Diego |
Na+/citrate transporter [SLC13A5] variants in epilepsy and developmental delay |
Hiroyuki Kusuhara, University of Tokyo |
Endogenous biomarkers for renal transporters |
Yurong Lai, Gilead Sciences |
Endogenous biomarkers for OATP1B: preclinical to clinical translation |
Mitchell Taub, Boehringer Ingelheim |
Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin |
Lei Zhang, U.S. Food and Drug Administration |
Regulatory Science Perspectives on Transporter-Mediated Drug-Drug Interactions |
Eva Gil Berglund, Medical Products Agency (Sweden) |
An European Perspective |
Xiaoyan Chu, Merck |
Evaluation of Dabigatrin Etexilate as a Clinical Probe for Pgp Inhibition: Comparison with Digoxin |
Justin Lutz, Gilead Sciences |
Induction: Drug Transporters versus Enzymes |
Imad Hanna, Novartis |
Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically-Based Pharmacokinetic Model |
Kari Morrissey, Genentech |
IVIVE of Transporter-Mediated Clinical Drug-Drug Interactions in Industry – An Update from the IQ Transporter Working Group |
ITCW3 Planning Committee
We would like to thank the following members of the ITCW3 Planning Committee
Name |
Affiliation |
Kim Brouwer |
University of North Carolina, Chapel Hill |
Aleksandra Galetin |
University of Manchester |
Kathy Giacomini |
University of California San Francisco |
Shiew-Mei Huang |
U.S. Food and Drug Administration |
Par Matsson |
Uppsala University |
Nilay Thakkar |
University of North Carolina, Chapel Hill |
Donald Tweedie |
Merck |
Maciej Zamek-Gliszczynski |
GSK |
Lei Zhang |
U.S. Food and Drug Administration |